Research
Global dementia cases are set to triple, but what does this mean, what are we doing and how can you help?
With global dementia cases are set to triple by 2050 to no fewer than 152 million, we share what you can do to help.
Difficulty hearing speech could be a risk factor for dementia
Research links the cocktail party problem with an increased risk of dementia in a study conducted at the University of Oxford. Alzheimer’s Research UK comments on the findings.
Our letter to Matt Hancock on aducanumab
Today the FDA in the US made a landmark decision to approve the Alzheimer’s drug aducanumab. The drug has been approved under the FDA’s Accelerated Approval pathway, which includes a requirement for Biogen, the pharmaceutical company that makes the drug, to conduct a further stage four clinical trial to collect evidence on its benefits to…
When could aducanumab reach the UK?
Today is a historic day for dementia research with the US Food and Drug Administration (FDA) announcing the first (conditional) licence of a new drug for Alzheimer’s disease in a generation.
Protecting dementia research
The COVID-19 pandemic is having a huge impact on all walks of life across the UK. Everyone has been affected. Our scientists are no exception. As a result of COVID-19, 95% of researchers told us they have had projects and trials delayed because of the virus, with one in five having had research projects cancelled…
Discovering dementia drugs
At Alzheimer’s Research UK, we are committed to finding treatments that slow or stop the diseases that cause dementia.
We won’t stop until we find them.
Can we predict how dementia will progress following a diagnosis?
When someone receives a diagnosis of dementia, little is known about how their condition will progress and affect that individual over time. This is because dementia affects every person differently, with a number of factors influencing progression such as having other health conditions, our level of cognitive reserve and whether a person takes medications to treat other conditions.
Six take homes from the Alzheimer’s Research UK Conference
The onset of spring means not only lighter and longer days but also the annual Alzheimer’s Research UK Research Conference.
Although we couldn’t meet in person this year, our team worked hard to recreate the event virtually and bring together dementia researchers from all around the world.
Phase 2 trial results show donanemab may slow decline in early Alzheimer’s
Data from a trial of the drug donanemab suggests the treatment may be able to slow decline in people with early Alzheimer’s disease.
Could your smartwatch hold clues to early Alzheimer’s disease?
More than a quarter of us own and use a wearable device. But what if some of the data they’re collecting could help scientists identify who was in the very early stages of a disease like Alzheimer’s, even before symptoms show?
